Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 15/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17159812 | 0.90 | CYP19A1 (0.80) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL15688800 | 0.84 | CYP19A1 (0.71) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL3235365 | 0.82 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6 | |
| SCHEMBL11354103 | 0.82 | CYP19A1 (0.69) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL4873932 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| SCHEMBL307542 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL3319920 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL3318872 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 | |
| SCHEMBL309621 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6UGT1A4PDE4D | |
| Hydrochloric Acid SCHEMBL11358575 | 0.81 | CYP19A1 (0.67) | CYP19A1HDAC1HDAC6CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115417859-B | Synthesis method of rizatriptan benzoate | 陕西师范大学 | 2024-02-02 | — | — | CN | claimed |
| CN-115417859-A | Synthetic method of rizatriptan benzoate | 陕西师范大学 | 2022-12-02 | — | — | CN | claimed |
| CN-115417859-B | Synthesis method of rizatriptan benzoate | 陕西师范大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-115417859-B | Synthesis method of rizatriptan benzoate | 陕西师范大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-115417859-A | Synthetic method of rizatriptan benzoate | 陕西师范大学 | 2022-12-02 | — | — | CN | disclosed |
| CN-115417859-A | Synthetic method of rizatriptan benzoate | 陕西师范大学 | 2022-12-02 | — | — | CN | disclosed |
| US-11439622-B2 | Inhibitors of metallo-beta-lactamases | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-09-13 | — | — | US | disclosed |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2020-12-03 | — | — | US | disclosed |
| EP-3383858-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| CN-108602795-A | The inhibitor of metal-beta-lactamase | 牛津大学科技创新有限公司 | 2018-09-28 | — | — | CN | disclosed |
| WO-2017093727-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| CN-1529697-A | Tricyclic compounds useful as angiotensin II agonists | ά�ƶ�ҩ�﹫˾ | 2004-09-15 | — | — | CN | disclosed |
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | VICORE PHARMA AB (SE) | 2004-08-26 | — | — | US | disclosed |
| EP-0490816-B1 | Fluoro-compounds and their use as aromatase inhibitors | CIBA GEIGY AG (CH) | 1997-07-09 | — | — | EP | disclosed |
| US-5637605-A | ANTITUMOR AGENTS | CIBA GEIGY CORPORATION (US) | 1997-06-10 | — | — | US | disclosed |
| US-5583128-A | ADMINISTERING A SIDE EFFECT REDUCED AROMATASE INHIBITOR | CIBA-GEIGY CORPORATION (US) | 1996-12-10 | — | — | US | disclosed |
| US-5457209-A | Antitumor agents | CIBA-GEIGY CORPORATION (US) | 1995-10-10 | — | — | US | disclosed |
| US-5376669-A | Antitumor agents | CIBA-GEIGY CORP. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5227393-A | estrogen-dependent diseases, anticancer | CIBA-GEIGY CORPORATION (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0490816-A2 | Fluoro-compounds | CIBA-GEIGY AG (CH) | 1992-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167176-A1 | Tricyclic compounds useful as angiotensin II agonists | AGTR1, AGTR2, NPY2R | CYP19A1 2703/4885HDAC1 1098/4885HDAC6 1678/4885 |
| US-11439622-B2 | Inhibitors of metallo-beta-lactamases | IDO1, MGAM, LCT | CYP19A1 1014/4885HDAC1 1152/4885HDAC6 956/4885 |
| US-20200375946-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | IDO1, MGAM, LCT | CYP19A1 1014/4885HDAC1 1152/4885HDAC6 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.